Showing results (1851-1860 of 14,093) with videos related to
Sort By:
Pageof 1,410
Gynecologic Oncology|February 24, 2000
Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancerT E Buekers, T A Lallas, R E BullerGynecologic Oncology|February 13, 2001
Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancerH Yabushita, M Shimazu, H Yamada, et al.Gynecologic Oncology|February 13, 2001
Distinguishing the benign and malignant adnexal mass: an external validation of prognostic modelsB W Mol, D Boll, M De Kanter, et al.Gynecologic Oncology|February 13, 2001
Effect of BPV1 E2-mediated inhibition of E6/E7 expression in HPV16-positive cervical carcinoma cellsM S Moon, C J Lee, S J Um, et al.Gynecologic Oncology|February 13, 2001
Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinomaM Hirai, A Nakagawara, T Oosaki, et al.Gynecologic Oncology|February 13, 2001
p53 mutation is infrequent in clear cell carcinoma of the ovaryE S Ho, C R Lai, Y T Hsieh, et al.Gynecologic Oncology|February 13, 2001
Nongestational pure ovarian choriocarcinoma with contralateral teratomaD Goswami, K Sharma, V Zutshi, et al.Gynecologic Oncology|August 6, 2000
The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based studyH O Smith, M F Tiffany, C R Qualls, et al.Gynecologic Oncology|August 6, 2000
Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasmsM Furuya, H Ishikura, Y Kawarada, et al.Gynecologic Oncology|August 6, 2000
Placebo-controlled trial of indole-3-carbinol in the treatment of CINM C Bell, P Crowley-Nowick, H L Bradlow, et al.Pageof 1,410